10 reports

  • BRISTOL-MYERS SQUIBB

PRODUCT CATEGORIES: ANTIVIRALS.

  • Antiviral
  • HIV AIDS
  • HIV Antiviral
  • Therapy
  • Bristol-Myers Squibb Company

Top ## players hold majority of stake in the market ##.

  • Antiviral
  • Hepatitis
  • Hepatitis Treatment
  • Therapy
  • Bristol-Myers Squibb Company

STRENGTH: ## LOW; ## HIGH F.

  • Antiviral
  • HIV AIDS
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc

Hepatitis C

4385 5000 3900
  • DIRECT-ACTING ANTIVIRALS TARGET KEY VIRAL NON-STRUCTURAL PROTEINS NECESSARY FOR HCV REPLICATION
  • Pipeline: Hepatitis C

Antiviral Therapy [Epub ahead of print] < DOI> ##. ##/ IMP##< / DOI>.

  • Antiviral
  • European Union
  • Japan
  • United States
  • Bristol-Myers Squibb Company

The company has also signed a deal worth $## billion with Moderna for its messenger RNA therapeutics platform in developing new antiviral vaccines and passive immunity therapies.

  • Antiviral
  • HIV AIDS
  • HIV Antiviral
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • 6.2 BRISTOL-MYERS SQUIBB (BMS) - CLINICAL TRIALS
  • 3. Hepatitis C - Approved Drugs Sales & Forecast

This study will evaluate the safety, tolerability and antiviral efficacy of Sofosbuvir with Ribavirin (RBV) participants with genotype ## or ## Hepatitis C virus (HCV) infection who have chronic renal insufficiency.

  • Antiviral
  • Hepatitis
  • Hepatitis Treatment
  • Therapy
  • Bristol-Myers Squibb Company

HIV

4385 5000 3900
  • ATTACHMENT AND FUSION
  • Current Treatment Options

Antiviral Therapy, ##(##), ##-## < DOI> ##. ##/ imp##< / DOI>.

  • Antiviral
  • HIV AIDS
  • Therapy
  • Product Initiative
  • Bristol-Myers Squibb Company
  • 3. Hepatitis C - Approved Drugs Sales & Forecast to
  • 4. Hepatitis C - Pipeline Drugs Sales & Forecast to 2020

Roche is developing mericitabine (R##), an investigational nucleoside inhibitor of NS##B HCV polymerase with antiviral activity against HCV genotypes ##-##.

  • Antiviral
  • Hepatitis
  • Hepatitis Treatment
  • Therapy
  • Bristol-Myers Squibb Company
  • HEPATITIS C - PIPELINE BY BRISTOL-MYERS SQUIBB CO, H1 2018
  • HEPATITIS C - DORMANT PROJECTS, H1 2018 (CONTD..1), H1 2018

At each dose level, patients with treatment-naïve genotype ## HCV will receive ## days of ACH-## to assess safety and antiviral activity.

  • Antiviral
  • Hepatitis
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company
  • HEPATITIS C - PIPELINE BY BRISTOL-MYERS SQUIBB CO, H2 2018
  • BIT-225 - DRUG PROFILE

All patients in the study received antiviral treatment prior to transplantation, mainly new recently approved antivirals.

  • Antiviral
  • Hepatitis
  • Hepatitis Treatment
  • Therapy
  • Bristol-Myers Squibb Company